Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPIT: Sublocade vs Suboxone in Opioid Use Disorder
NCT05594121Phase 4Unknown
- Sponsor
- Royal Victoria Regional Health Centre
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of buprenorphine extended-release injection in opioid use disorder (OUD) (2 arms), sponsored by Royal Victoria Regional Health Centre. Primary endpoints: Opioid positivity at 12 months and Healthcare utilization at 12 months. Status: unknown.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05594121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594121.